CAR T approaches to bypass immune‑suppressing T cells in B‑cell lymphoma
Designing Chimeric Antigen Receptor Therapies to Overcome Treg Suppression
New CAR T cell strategies aim to help people with relapsed or treatment‑resistant large B‑cell lymphoma whose treatments are blocked by regulatory T cells.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11197507 on NIH RePORTER |
What this research studies
Researchers plan to engineer patients' own T cells (CAR T cells) so they resist suppression from regulatory T cells that can blunt anti‑tumor activity. The team builds on successful CD19 and CD22 CAR approaches and uses lab models, blood-based tumor DNA monitoring, and samples from patients to pinpoint mechanisms of resistance. Promising CAR designs that overcome Treg suppression would be moved toward early human testing with cell collection (apheresis) and infusions provided at the treating center.
Who could benefit from this research
Good fit: Ideal candidates are people with relapsed or refractory large B‑cell lymphoma who are eligible for autologous CAR T therapy, including those previously treated with CD19 CAR T cells.
Not a fit: Patients with cancers unrelated to B‑cell lymphoma, those ineligible for apheresis or autologous cell therapy, or patients with very poor overall health may not benefit from this work.
Why it matters
Potential benefit: If successful, these approaches could increase the number of patients who achieve long‑lasting remissions after CAR T therapy for large B‑cell lymphoma.
How similar studies have performed: Earlier CAR T therapies targeting CD19 and newer CD22 CARs have produced durable remissions in many patients, but directly overcoming regulatory T cell–mediated resistance is a newer, less‑tested approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Mackall, Crystal — Stanford University
- Study coordinator: Mackall, Crystal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.